Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and
Danièle Taras1, Jean-Frédéric Blanc, Anne Rullier
1INSERM E362, Bordeaux F-33076, France.
Journal of Hepatology
|August 29, 2006
Summary
Pravastatin significantly reduced hepatocellular carcinoma (HCC) progression and metastasis in rats by decreasing matrix metalloproteinase (MMP) activity. These findings suggest statins may benefit human HCC treatment.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Statins demonstrate efficacy in early hepatocellular carcinoma (HCC) models.
- Established HCC progression requires further investigation for therapeutic interventions.
Purpose of the Study:
- To evaluate pravastatin's effect on established rat HCC progression.
- To elucidate the mechanisms underlying pravastatin's action in HCC.
Main Methods:
- Hepatocellular carcinoma (HCC) induced in rats using diethylnitrosamine and N-nitrosomorpholine.
- Rats with established HCC received pravastatin or solvent for 10 weeks.
Main Results:
- Pravastatin treatment reduced liver tumor burden and liver weight/body weight ratio.
- Pravastatin significantly decreased lung metastasis incidence and surface area.
- Pravastatin suppressed matrix metalloproteinase (MMP)-2 and MMP-9 activity, potentially by downregulating MMP-14 and tissue inhibitor of matrix metalloproteinases-2.
Conclusions:
- Pravastatin effectively inhibits progression and metastatic spread of established HCC in a rat model.
- Reduced MMP activity is a likely mechanism for pravastatin's anti-cancer effects.
- Findings support the potential of statins as a therapeutic strategy for human HCC.
